Ernexa Therapeutics says its lead cancer candidate, ERNA-101, is on schedule for an Investigational New Drug (IND) submission in the third quarter of 2026. The Cambridge, Mass., company (Nasdaq: ERNA) said on June 17, 2026, that process development is finished and GMP production is underway.
If the IND goes as planned, Ernexa expects to start a first-in-human Phase 1 study in the fourth quarter of 2026 and become a clinical-stage biotechnology company.
“ERNA-101 continues to advance toward the clinic as we execute across manufacturing, regulatory and clinical development activities,” said Sanjeev Luther, President and Chief Executive Officer. “With GMP manufacturing underway, technology transfer activities progressing and our IND submission expected in the third quarter of 2026, we believe we are entering one of the most important periods in the Company’s history.”
How the therapy is meant to work
ERNA-101 is an engineered, allogeneic induced mesenchymal stem cell therapy made from induced pluripotent stem cells. In plain terms, the cells come from a master cell line rather than from each patient. They are designed to home in on tumors and release a proprietary IL-7/IL-15 fusion cytokine inside the tumor microenvironment.
The target is the “cold” tumor, one that escapes immune recognition and often does not respond to existing therapies. Ernexa says the therapy activates T cells and natural killer cells and reshapes the local tumor environment, with the aim of improving responses to checkpoint inhibitors.
Preclinical results and the money
In preclinical studies pairing ERNA-101 with PD-1 blockade, the company reported complete elimination of detectable tumors and 100% long-term survival through study follow-up. Tumors showed more CD4+ and CD8+ T cells, and tumor-associated macrophages were reprogrammed into a tumor-fighting phenotype. Tumor burden and malignant ascites fell significantly. The combination did substantially better than either treatment alone, according to Ernexa. These are results from preclinical ovarian cancer models, not from people.
Ernexa also completed a $10.5 million financing. It believes that gives it enough resources for the next 12 to 18 months, a period in which it lists the first GMP clinical batch, the IND filing, the first Phase 1 patient in platinum-resistant ovarian cancer and a pre-IND meeting with the FDA for its autoimmune program, ERNA-201. The company’s FDA Pre-IND meeting for ERNA-101 is already complete.
Luther called the planned study “a defining milestone for Ernexa.” He said the company believes ERNA-101 could improve outcomes for patients with platinum-resistant ovarian cancer and set up a new approach for cold tumors across several cancer types.
The therapy has not been tested in humans, and anyone with questions about cancer treatment should consult their doctor.
